2023-07-25 10:19:40 ET
Stoke Therapeutics ( NASDAQ: STOK ) lost ~30% in value on Tuesday after the company announced new data from its Phase 1/2a Studies for the antisense oligonucleotide STK-001 targeted at patients with Dravet syndrome, a hereditary form of epilepsy.
Citing data from ongoing trials named MONARCH and ADMIRAL, Stoke ( STOK ) said that 74 patients aged 2 to 18 who received the therapy tolerated STK-001 well at single or multiple doses ranging from 10mg – 70mg.
However, 32% of patients experienced a treatment-emergent adverse event related to STK-001, and 20% experienced a treatment-emergent serious adverse event.
In terms of efficacy, at the highest dose of 70mg, the mean reductions in convulsive seizure frequency reached 80% (n = 6) and 89% (n = 3) from baseline to three months and six months after the last dose, respectively.
The mean reduction in convulsive seizure frequency stood at 19% (n = 14) and 45% (n = 8) at three months and six months, respectively, after the last dose among the 16 patients who received the 45mg dose.
The company plans to release additional Phase 1/2a data for STK-001 in H1 2024, along with its late- stage plans for the drug.
In December, citing an interim analysis of six patients who received STK-001 at 45 mg, Stoke ( STOK ) reported a 55% reduction in convulsive seizure frequency from baseline to three months after receiving the last dose.
More on Stoke
- Stoke Therapeutics upgraded to neutral at BoA on Dravet candidate
- Stoke Therapeutics Looks Unfairly Valued
For further details see:
Stoke Therapeutics plunges after Phase 1/2 data for epilepsy drug